

RECEIVED
CENTRAL FAX CENTER

001/025

JUL 29 2005



Vertex Pharmaceuticals Incorporated
130 Waverly Street • Cambridge, MA 02139-4242
Tel. 617.444.6100 • Fax 617.444.6483
<http://www.vpharm.com>

FAX TRANSMISSION

| | |
|---------------------|------------------------|
| To | 571-273-8300 |
| Examiner | Deborah C. Lambkin |
| Group Art Unit | 1626 |
| From | Karen E. Brown |
| Date | July 29, 2005 |
| Application No. | 10/688,613 |
| Attorney Docket No. | VPI/00-102 CON DIV3 US |
| Total Pages | 22 |

Message or Comment

If any problems occur with this fax transmittal, please call (617) 444-6168 immediately.

RECEIVED
OIPF/IAP

AUG 01 2005

Rev. 3/8/05

RECEIVED
CENTRAL FAX CENTER
JUL 29 2005


VPI/00-102 CON DIV3 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/688,613
Confirmation No.: 2448
Filing Date: October 17, 2003
Examiner: Deborah C. Lambkin
Group Art Unit: 1626
Applicants: Michael Hale et al.
For: PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF
ERK

Certificate of Facsimile Transmission Under 37 CFR 1.8

I hereby certify that this correspondence and any documents referred to as attached hereto is/are being facsimile transmitted to the United States Patent and Trademark Office on July 29, 2005.


Signature

Susan Batty-Gunn
Typed or Printed Name

08/01/2005 HTECKLU1 00000011 500725 10688613

01 FC:1253 1020.00 DA

July 29, 2005
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] a Reply to Office Action; [] a Petition for Extension of Time; [] a substitute Specification; [] a Declaration; [] a Supplemental Declaration; [] a Power of Attorney; [] an Associate Power of Attorney; [] formal drawings; [] Notice of Appeal; [] Appeal Brief; [X] Terminal Disclaimer; to be filed in the above-identified patent application.

RECEIVED
CENTRAL FAX CENTER

JUL 29 2005

Applicants: Michael Hale et al.
Application No.: 10/688,613

FEE FOR ADDITIONAL CLAIMS

☒ A fee for additional claims is not required.

☐ A fee for additional claims is required.

The additional fee has been calculated as shown below:

| CLAIMS REMAINING AFTER AMENDMENT | HIGHEST NUMBER PREVIOUSLY PAID FOR | PRESENT EXTRA | RATE | ADDITIONAL FEES |
|---|---|------------------|--------|--------------------|
| TOTAL CLAIMS | 24 | - | 24 * = | X \$ 50 = \$ 0 |
| INDEPENDENT CLAIMS | 1 | - | 3 ** = | X \$ 200 = \$ 0 |
| FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM | | | + | \$ 360 = \$ |

* If less than 20, insert 20. TOTAL \$ 0
** If less than 3, insert 3.

☐ A check in the amount of \$___ in payment of the filing fee is transmitted herewith.

☐ Please charge \$___ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

RECEIVED
CENTRAL FAX CENTER

004/025

JUL 29 2005

Applicants: Michael Hale et al.
Application No.: 10/688,613


EXTENSION FEE

- ☒ [X] The following extension is applicable to the Response filed herewith; ☐ [] \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); ☐ [] \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); ☒ [X] \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); ☐ [] \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); ☐ [] \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
- ☐ [] A check in the amount of ☐ [] \$120.00; ☐ [] \$450.00; ☐ [] \$1,020.00; ☐ [] \$1,590.00; ☐ [] \$2,160.00 in payment of the extension fee is transmitted herewith.
- ☒ [X] Please charge the extension fee in the amount of ☐ [] \$120.00; ☐ [] \$450.00; ☒ [X] \$1,020.00; ☐ [] \$1,590.00; ☐ [] \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ [X] The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

- ☐ [] Please charge \$_____ to Deposit Account No. 50-0725 for _____.

Respectfully submitted,


Karen E. Brown, Reg. No. 43,866
Attorney/Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483

JUL 29 2005

Attorney Docket No. VPI/00-102 CON DIV3 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/688,613
Confirmation No.: 2448
Filing Date: October 17, 2003
Examiner: Deborah C. Lambkin
Group Art Unit: 1626
Applicants: Michael Hale et al.
For: PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF
ERK

July 29, 2005
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND REPLY TO OFFICE ACTION

Sir:

This is in response to the January 31, 2005 Office Action in the above-identified application. Applicants have concurrently herewith submitted a petition to extend the time for a reply by three month(s), up to and including July 31, 2005, and have authorized the Director to charge to Deposit Account No. 50-0725 the applicable fee under 37 C.F.R. § 1.17(a)(3). Consequently, this reply is timely submitted.

Amendments to the claims begin on page 2 of this Reply.

Remarks begin at page 12 of this Reply.

Rev. 3/8/05